On this page you will find our recommendations sorted by BNF chapter.

Appraisal Reports are available to stakeholders on request.

Where a decision is >24 months old; these are highlighted in red. If you are a clinician working within the NTAG region and would like to prioritise an old decision for re-review please contact the professional secretary on nuth.nyrdtc.rxsupp@nhs.net

Title Documents Decision Date
Anti-vascular endothelial growth factor therapies (bevacizumab or ranibizumab) as an adjunct to vitrectomy in diabetic retinopathy (NETAG) Recommendation Not recommended 07/07/2009
Bevacizumab (Avastin®) for age-related macular degeneration (Updated) Recommendation Recommended as an option 09/09/2014
Bevacizumab (Avastin®) for diabetic macular oedema (NETAG) Recommendation Not recommended 10/07/2012
Bevacizumab (Avastin®) for neovascular glaucoma secondary to central retinal vein occlusion (NETAG) Recommendation Not recommended 12/04/2011
Bevacizumab (Avastin®) or ranibizumab (Lucentis®) for macular oedema secondary to retinal vein occlusion(s)(NETAG) Recommendation Bevacizumab (Avastin®) 1.25 mg using a ‘when required’ (PRN) regimen is recommended for management of macular oedema secondary to retinal vein occlusion 18/01/2011
Bevacizumab (Avastin®) or ranibizumab (Lucentis®) for non-AMD choriodal neovascular disease (NETAG) Recommendation Treatment guidelines Recommends bevacizumab intravitreal injection using a ‘when required’ dose regimen for the treatment of non-AMD CNV, as described in the North East Retinal Group treatment guideline 08/10/2009
High dose multivitamins and minerals for the prevention of progression of age-related macular degeneration Recommendation Not recommended 03/06/2014
Intraocular telescope by VisionCare™ for age-related macular degeneration (NETAG) Recommendation Not recommended 13/11/2012
Sequential pharmacological therapies in the management of macular oedema secondary to retinal vein occlusion Recommendation RVO treatment pathway Recommended 09/09/2014
Verteporfin (Visudyne®) with photo-dynamic therapy for chronic central serous chorioretinopathy Updated recommendation Recommended 02/06/2020